References
- Utermann G. Lipoprotein(a): a genetic risk factor for premature coronary heart disease. Curr Opin Lipidol 1990; 1: 404–10
- Kostner G M, Avogaro P, Cazzolato G, Marth E, Bittolo-Bon G, Qunici G B. Lipoprotein Lp(a) and the risk for myocardial infarction. Atherosclerosis 1981; 38: 51–61
- Kraft H G, Menzel H J, Hoppichler F, Vogel W, Utermann G. Changes of genetic apolipoprotein phenotypes caused by liver transplantations: implications for apolipoprotein synthesis. J Clin Invest 1989; 83: 137–42
- Rainwater D L, Lanford R E. Production of lipoprotein(a) by primary baboon hepatocytes. Bio-chim Biophys Acta 1989; 1003: 30–5
- Maeda S, Abe A, Seishma M, Makino K, Noma A, Kawade M. Transient changes of serum lipoprotein(a) as an acute phase protein. Atherosclerosis 1989; 78: 145–50
- Brown M S, Goldstein J L. Plasma lipoproteins. Teaching old dogmas new tricks. Nature 1987; 330: 113–4
- Albers J J, Hazard W R. Immunochemical quantitation of human plasma Lp(a). Lipids 1974; 9: 15–26
- Utermann G. The mysteries of lipoprotein(a). Science 1989; 246: 904–10
- Albers J J, Adolphson J L, Hazzard W R. Radioimmunoassay of plasma Lp(a) lipoprotein. J Lipids Res 1977; 18: 331–8
- Ehnholm C H, Garoff K S, Aro H. Purification and quantitation of the human plasma lipoprotein carrying the Lp(a) antigen. Biochim Biophys Acta 1971; 236: 431–9
- Utermann G, Menzel H J, Kraft H G, Duba H C, Kemmler H G, Seitz C. Lp(a) glycoprotein pheno-type inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest 1987; 80: 458–65
- Parra H J, Mezdour H, Cachera C, Dracon M, Tacquet A, Fruchart J C. Lp(a) lipoprotein in patients with chronic renal failure treated by hemodialysis. Clin Chem 1987; 33: 721
- Kawade M. Studies on the Lp(a) hpoprotein in Japanese. Jpn J Clin Pathol 1983; 31: 391–5
- Feely J, Barry M, Keeling P WN, Weir D G, Cooke T. Lipoprotein) in cirrhosis. BMJ 1992; 304: 545–6
- van Wersch J WJ, Russel M GVM, Lustermans F AT. The extent of diffuse intravascular coagulation and fibrinolysis in patients with liver cirrhosis. Eur J Clin Chem Clin Biochem 1992; 30: 275–9
- Wright L C, Sullivan D R, Muller M, Dyne M, Tattersall M HN, Mountford C E. Elevated apoli-poprotein(a) levels in cancer patients. Int J Cancer 1989; 43: 241–4
- Csaszar A, Dieplinger H, Sandholzer C, et al. Plasma lipoprotein (a) concentration and phenotypes in diabetes mellitus. Diabetologia 1993; 36: 47–51
- Winocour P H, Durrington P N, Bhatnagar D, Mbewu A D, Ishola M, Mackness M, Arrol S. A cross-sectional evaluation of cardiovascular risk factors in coronary heart disease associated with type 1 (insulin-dependent) diabetes mellitus. Diabetes Res Clin Pract 1992; 18: 173–84
- Haffner S M, Gruber K K, Morales P A, Hazuda H P, Valdez R A, Mitchell B D, Stern M P. Lipopro-tein(a) concentrations in Mexican Americans and non-Hispanic whites: the San Antonio Heart Study. Am J Epidemiol 1992; 136: 1060–8
- Klausen I C, Schmidt E B, Lervang H H, Gerdes L U, Ditzel J, Faergeman O. Normal lipoprotein) concentrations and apolipoprotein(a) iso-forms in patients with insulin-dependent diabetes mellitus. Eur J Clin Invest 1992; 22: 538–41
- Gall M A, Rossing P, Hommel E, et al. Apolipoprotein(a) in insulin-dependent diabetic patients with and without diabetic nephropathy. Scand J Clin Lab Invest 1992; 52: 513–21
- Haffner S M, Morales P A, Stern M P, Gruber M K. Lp(a) concentrations in NIDDM. Diabetes 1992; 41: 1267–72
- van Wersch J WJ, Rompelberg-Lahaye J, Lustermans F AT. Plasma concentration of coagulation and fibrinolysis factors and the level of platelet function in hypertension. Eur J Clin Chem Clin Biochem 1991; 29: 375–9
- van Wersch J WJ, Tjwa M KT. The coagulation/ fibrinolysis balance and lung cancer. Haemostasis 1991; 21: 117–23